Float Short %

8.68

Margin Of Safety %

Put/Call OI Ratio

0.57

EPS Next Q Diff

0.68

EPS Last/This Y

EPS This/Next Y

0.18

Price

9.57

Target Price

31.38

Analyst Recom

1.56

Performance Q

36.13

Relative Volume

0.34

Beta

1.14

Ticker: VIR

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	VIR	11.19	0.76	0.09	16864
2025-01-24	VIR	10.57	0.71	0.42	17437
2025-01-27	VIR	10.29	0.66	9.37	17781
2025-01-28	VIR	10.58	0.75	0.09	18832
2025-01-29	VIR	10.91	0.74	0.09	18885
2025-01-30	VIR	10.3	0.74	0.20	18845
2025-01-31	VIR	10.38	0.74	43.76	18801
2025-02-03	VIR	9.97	0.59	0.16	17104
2025-02-04	VIR	9.69	0.58	0.24	17290
2025-02-05	VIR	10.04	0.57	0.41	17511
2025-02-06	VIR	10.23	0.58	0.89	17569
2025-02-07	VIR	9.85	0.58	1.38	17607
2025-02-10	VIR	9.39	0.57	0.30	17605
2025-02-11	VIR	9.08	0.58	0.83	17731
2025-02-12	VIR	9.12	0.58	0.02	17765
2025-02-13	VIR	9.57	0.57	0.00	17925
2025-02-14	VIR	9.65	0.57	0.34	17931
2025-02-18	VIR	9.69	0.57	0.15	17945
2025-02-19	VIR	9.85	0.57	0.01	17959
2025-02-20	VIR	9.8	0.57	0.00	17823
2025-02-21	VIR	9.58	0.57	1.31	17823
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	VIR	11.20	-1.2	-	-3.92
2025-01-24	VIR	10.65	-1.2	-	-3.92
2025-01-27	VIR	10.28	-1.2	-	-3.92
2025-01-28	VIR	10.59	-1.2	-	-3.92
2025-01-29	VIR	10.90	-1.2	-	-3.92
2025-01-30	VIR	10.31	-1.2	-	-3.92
2025-01-31	VIR	10.38	-1.2	-	-3.92
2025-02-03	VIR	9.98	-1.2	-	-3.92
2025-02-04	VIR	9.69	-1.2	-	-3.92
2025-02-05	VIR	10.03	-1.2	-	-3.92
2025-02-06	VIR	10.23	-1.2	-	-3.92
2025-02-07	VIR	9.84	-1.2	-	-3.92
2025-02-10	VIR	9.38	-1.2	-	-3.92
2025-02-11	VIR	9.07	-1.2	-	-3.92
2025-02-12	VIR	9.11	-1.2	-	-3.92
2025-02-13	VIR	9.58	-1.2	-	-3.92
2025-02-14	VIR	9.65	-1.2	-	-3.92
2025-02-18	VIR	9.68	-1.2	-	-3.92
2025-02-19	VIR	9.85	-1.2	-	-3.92
2025-02-20	VIR	9.80	-1.2	-	-3.92
2025-02-21	VIR	9.57	-1.2	-	-3.92
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	VIR	-0.06	-1.17	7.47
2025-01-24	VIR	-0.06	-1.17	7.47
2025-01-27	VIR	-0.06	-1.40	7.47
2025-01-28	VIR	-0.06	-1.40	8.96
2025-01-29	VIR	-0.06	-1.40	8.96
2025-01-30	VIR	-0.06	-1.40	8.96
2025-01-31	VIR	-0.06	-1.40	8.96
2025-02-03	VIR	-0.06	-0.56	8.96
2025-02-04	VIR	-0.06	-0.56	8.96
2025-02-05	VIR	-0.06	-0.56	8.96
2025-02-06	VIR	-0.06	-0.56	8.96
2025-02-07	VIR	-0.06	-0.56	8.96
2025-02-10	VIR	-0.06	-0.86	8.95
2025-02-11	VIR	-0.06	-0.86	8.95
2025-02-12	VIR	-0.06	-0.86	8.71
2025-02-13	VIR	-0.06	-0.86	8.71
2025-02-14	VIR	-0.06	-0.86	8.71
2025-02-18	VIR	-0.07	0.27	8.67
2025-02-19	VIR	-0.07	0.27	8.67
2025-02-20	VIR	-0.09	0.27	8.67
2025-02-21	VIR	-0.09	0.27	8.68
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.56

Avg. EPS Est. Current Quarter

-0.87

Avg. EPS Est. Next Quarter

-0.88

Insider Transactions

-0.09

Institutional Transactions

0.27

Beta

1.14

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

93.2

Max Drawdown 5-Year %

-91.9

Target Price

31.38

P/E

Forward P/E

PEG

P/S

16.76

P/B

1.05

P/Free Cash Flow

EPS

-3.92

Average EPS Est. Cur. Y

-3.92

EPS Next Y. (Est.)

-3.74

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-678.4

Relative Volume

0.34

Return on Equity vs Sector %

-62.2

Return on Equity vs Industry %

-46.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.49

EBIT Estimation

Vir Biotechnology, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 587

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

stock quote shares VIR – Vir Biotechnology, Inc. Stock Price stock today

news today VIR – Vir Biotechnology, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch VIR – Vir Biotechnology, Inc. yahoo finance google finance

stock history VIR – Vir Biotechnology, Inc. invest stock market

stock prices VIR premarket after hours

ticker VIR fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: VIR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y